Expertise in
1
conditions

Milena P. Mak

Department Of Thoracic/Head And Neck Medical Oncology, 
Sao Paulo, SP, BR 
Expertise in
1
conditions
Department Of Thoracic/Head And Neck Medical Oncology, 
Sao Paulo, SP, BR 

Overview

Milena Mak practices practicing medicine in Sao Paulo, Brazil.

Ms. Mak is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Acinic Cell Carcinoma of Salivary Glands, and Non-Small Cell Lung Cancer (NSCLC).

She is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Department Of Thoracic/Head And Neck Medical Oncology, Sao Paulo, SP, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Enrollment Status: Terminated
Publish Date: February 19, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
View 2 Less Clinical Trials

34 Total Publications

Malignant salivary gland tumors in Brazil: epidemiology, treatment patterns, and survival outcomes in public Brazilian population.
Malignant salivary gland tumors in Brazil: epidemiology, treatment patterns, and survival outcomes in public Brazilian population.
Journal: Gland surgery
Published: November 26, 2025

Frequently Asked Questions about Milena P. Mak

Is Milena P. Mak a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Milena P. Mak is classified as an Advanced expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Milena P. Mak participate in research or clinical trials?

Yes. Milena P. Mak has published 34 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Milena P. Mak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mak's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile